Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.
Gargini R, Segura-Collar B, Herránz B, García-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, Seoane J, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A, Castro MG, García-Escudero R, Ávila J, Sánchez-Gómez P. Gargini R, et al. Sci Transl Med. 2020 Jan 22;12(527):eaax1501. doi: 10.1126/scitranslmed.aax1501. Sci Transl Med. 2020. PMID: 31969485 Free PMC article.
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Rodón J, et al. Invest New Drugs. 2015 Apr;33(2):357-70. doi: 10.1007/s10637-014-0192-4. Epub 2014 Dec 23. Invest New Drugs. 2015. PMID: 25529192 Free PMC article. Clinical Trial.
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A. Sepúlveda-Sánchez JM, et al. Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105. Neuro Oncol. 2017. PMID: 28575464 Free PMC article. Clinical Trial.
Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma.
Hernández-SanMiguel E, Gargini R, Cejalvo T, Segura-Collar B, Núñez-Hervada P, Hortigüela R, Sepúlveda-Sánchez JM, Hernández-Laín A, Pérez-Núñez A, Sanz E, Sánchez-Gómez P. Hernández-SanMiguel E, et al. Oxid Med Cell Longev. 2019 Aug 5;2019:9719730. doi: 10.1155/2019/9719730. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31467641 Free PMC article.
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
Sepúlveda-Sánchez JM, Gil-Gil M, Alonso-García M, Vaz Salgado MÁ, Vicente E, Mesía Barroso C, Rodríguez Sánchez Á, Durán G, De Las Peñas R, Muñoz-Langa J, Velasco G, Hernández-Laín A, Hilario A, Navarro Martín M, Benavides M, Oleaga L, Cantero Montenegro D, Ruano Y, Sánchez-Gómez P, Martín-Soberón MC, Morales-Llombart R, Pachón V, Pineda E. Sepúlveda-Sánchez JM, et al. Target Oncol. 2020 Oct;15(5):613-622. doi: 10.1007/s11523-020-00754-6. Target Oncol. 2020. PMID: 33025213 Clinical Trial.
Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype.
Cejalvo T, Gargini R, Segura-Collar B, Mata-Martínez P, Herranz B, Cantero D, Ruano Y, García-Pérez D, Pérez-Núñez Á, Ramos A, Hernández-Laín A, Martín-Soberón MC, Sánchez-Gómez P, Sepúlveda-Sánchez JM. Cejalvo T, et al. Cancers (Basel). 2020 Nov 2;12(11):3230. doi: 10.3390/cancers12113230. Cancers (Basel). 2020. PMID: 33147752 Free PMC article.
Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas.
Segura-Collar B, Garranzo-Asensio M, Herranz B, Hernández-SanMiguel E, Cejalvo T, Casas BS, Matheu A, Pérez-Núñez Á, Sepúlveda-Sánchez JM, Hernández-Laín A, Palma V, Gargini R, Sánchez-Gómez P. Segura-Collar B, et al. Cancer Res. 2021 Apr 15;81(8):2142-2156. doi: 10.1158/0008-5472.CAN-20-3558. Epub 2021 Feb 16. Cancer Res. 2021. PMID: 33593822 Free article.
IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas.
Gargini R, Segura-Collar B, Garranzo-Asensio M, Hortigüela R, Iglesias-Hernández P, Lobato-Alonso D, Moreno-Raja M, Esteban-Martin S, Sepúlveda-Sánchez JM, Nevola L, Sánchez-Gómez P. Gargini R, et al. Among authors: sepulveda sanchez jm. Neurotherapeutics. 2022 Jan;19(1):408-420. doi: 10.1007/s13311-021-01176-6. Epub 2022 Jan 31. Neurotherapeutics. 2022. PMID: 35099769 Free PMC article.
On optimal temozolomide scheduling for slowly growing glioblastomas.
Segura-Collar B, Jiménez-Sánchez J, Gargini R, Dragoj M, Sepúlveda-Sánchez JM, Pešić M, Ramírez MA, Ayala-Hernández LE, Sánchez-Gómez P, Pérez-García VM. Segura-Collar B, et al. Among authors: sepulveda sanchez jm. Neurooncol Adv. 2022 Sep 27;4(1):vdac155. doi: 10.1093/noajnl/vdac155. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36325374 Free PMC article.
48 results